Business context and reporting period
Concord Medical Services Holdings Limited’s Form 20-F reports the fiscal year ended December 31, 2020; it is an annual filing, not a standalone fourth-quarter report. The company operates radiotherapy and diagnostic-imaging centers in China and is expanding into owned cancer hospitals and imaging services. At year-end, its network comprised 27 cooperative centers in 20 hospitals. Financial statements are prepared under U.S. GAAP and reported in Renminbi (RMB); U.S. dollar figures are convenience translations.
Key financial metrics
Amounts below are RMB millions unless stated otherwise.
| Metric | 2020 | 2019 | Change / context |
|---|---|---|---|
| Revenue, net of VAT | 223.0 | 198.4 | Up 12.4% |
| Gross profit (loss) | 13.1 | (15.8) | Gross margin 5.9%, versus (8.0%) |
| Operating loss | (316.0) | (437.3) | Improved, partly due to lower impairment charges |
| Net loss | (404.0) | (352.1) | Widened; net loss attributable to Concord Medical was RMB310.0 million |
| Basic/diluted loss per share | RMB(5.11) | RMB(4.24) | Loss per ADS was RMB(15.33) |
| Operating cash flow | (229.8) | (195.3) | Cash use increased |
| Investing cash flow | (533.9) | (1,071.5) | Lower outflow than prior year |
| Financing cash flow | 1,138.3 | 513.3 | Supported by borrowings and redeemable noncontrolling-interest funding |
Revenue mix shifted: network revenue fell 4.5% to RMB116.0 million, while hospital revenue rose 39.3% to RMB107.1 million. Hospital operations remained loss-making at the gross-profit level: gross loss was RMB50.2 million, compared with RMB63.2 million gross profit for the network segment.
Financial position and material changes
- Cash and cash equivalents were RMB334.3 million; restricted cash was RMB112.1 million. Working capital was positive at RMB163.9 million.
- Bank and other borrowings totaled RMB2,116.9 million, including RMB148.9 million current. Total liabilities were RMB2,933.7 million. Contingently redeemable noncontrolling interests, classified as mezzanine equity, were RMB2,913.7 million; total shareholders’ deficit was RMB512.8 million.
- Capital expenditures were RMB948.3 million in 2020. Management estimated 2021 capex of approximately RMB1.0 billion, mainly for hospital construction and equipment in Shanghai, Guangzhou and Beijing.
- The company sold 90% of its Singapore hospital subsidiary in November 2020 and ceased control; the disposal generated a RMB14.9 million loss. It retained a 10% investment.
- Construction of the Beijing Proton Medical Center was delayed by COVID-19 and a shareholder’s failure to perform obligations. Shanghai cancer-center construction was also delayed. Guangzhou Concord Cancer Center began operating in June 2021, after the reporting period.
Outlook, risks and unusual items
- COVID-19 reduced patient volumes and network revenue; eight cooperative centers temporarily suspended operations for about five weeks on average. The filing says uncertainty about future pandemic effects remains.
- Management said subsequent financing alleviated substantial doubt about going concern: RMB400 million of subsidiary capital investment, approximately RMB97.9 million of convertible bonds, and RMB418.4 million of bank credit facilities and loans were reported in 2021. However, the auditor’s report still includes a going-concern discussion and notes substantial doubt; funding availability and timing remain uncertain.
- Interest expense rose to RMB81.4 million from RMB28.7 million, while foreign exchange moved from a RMB35.0 million gain to a RMB58.7 million loss. These items contributed to the higher net loss.
- Noncontrolling investors in the subsidiary MHM have contingent redemption rights if a qualified IPO is not completed by June 30, 2024. The resulting accretion was RMB359.9 million in 2020 and is included in the calculation of loss per share.
- Management reported ineffective disclosure controls and internal control over financial reporting at year-end due to insufficient U.S. GAAP expertise for complex accounting matters, including investment recoverability and employee-expense tax assessments.
- The 2020 audit was performed by Shandong Haoxin, engaged in August 2021 after EY Hua Ming was dismissed. The filing says the change was not due to disagreements, but notes EY had not completed the 2020 audit while three matters remained unresolved: going concern, recoverability of a distressed-asset fund investment, and payments to a service provider partly owned by employees.
- Other key exposures include dependence on hospital partners and permits, concentrated suppliers, capital-intensive hospital projects, potential difficulty recruiting clinicians, and regulatory, reimbursement, foreign-exchange and audit-access risks in China.
Important facts for investors to verify
- Whether 2021 financing was received and remains available, and whether liquidity covers operating cash burn, debt service and the planned capex program.
- The terms, redemption triggers and funding consequences of the RMB2,913.7 million contingently redeemable noncontrolling interests, including the 2024 IPO condition.
- Progress, remaining costs, approvals and opening timelines for the Beijing, Shanghai and Guangzhou hospital projects, and their expected utilization and profitability.
- Whether the material weakness in financial reporting controls has been remediated, and the status of the matters that delayed the prior auditor’s 2020 audit.
- Collection of hospital-partner receivables and exposure to the five largest customers and suppliers; top five customers accounted for 25.9% of 2020 revenue, while the five largest suppliers represented 95% of medical-equipment and construction purchases.
- Underlying operating performance excluding noncash impairment, financing, foreign-exchange and redeemable-interest effects, and the sustainability of the shift toward hospital revenue.